Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

41.71 +0.10 (+0.24%)
Streaming Delayed Price Updated: 9:43 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gsk Plc ADR

< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Dreary Day
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
Via Talk Markets
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Why iTeos Therapeutics Stock Soared Today
The biotech struck a potential $2 billion deal with a pharmaceutical giant. 
Via The Motley Fool
iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK
iTeos Therapeutics (NASDAQ: ITOS) and GlaxoSmithKline plc (NYSE: GSK) have agreed to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal... 
Via Benzinga
3 Dividend Stocks Wall Street Thinks Will Soar 20% or More
Attractive dividends plus strong growth? Yes, please. 
Via The Motley Fool
Wednesday News And Catch-Up
Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Juvenile Investing Mob
Tech stocks did well in Europe but not in the US. The data are unconvincing. 
Via Talk Markets
VBI Vaccines' Brain Cancer Immunotherapy Gets FDA Fast Track Review; Announces Updated Tumor Response, Overall Survival Data
The FDA has granted Fast Track Designation for VBI Vaccines Inc's (NASDAQ: VBIV) VBI-1901, its cancer vaccine immunotherapeutic candidate to treat... 
Via Benzinga
Exposures Product Safety
Fan Hit
The 10-yr US treasury yield rose to 1.6% again. Later in the day, a rally was attempted, mostly for the meme shares. 
Via Talk Markets
'Halftime Report' Traders Weigh In On GlaxoSmithKline, Snowflake And More
On CNBC's "Fast Money Halftime Report," Jenny Harrington said GlaxoSmithKline plc (NYSE: GSK) has performed terribly, but we could be at a beginning of value... 
Via Benzinga
Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover
MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high. 
Via Investor's Business Daily
Activist Hedge Fund Elliott Questions GSK CEO Walmsley's Leadership: Mail on Sunday
GlaxoSmithKline Plc (NYSE: GSK) appeared to dodge a potential shakeup last week when Elliott Management said it would not push the sale of its vaccines and... 
Via Benzinga
A Look Into GlaxoSmithKline's Price Over Earnings
Right now, GlaxoSmithKline Inc. (NYSE:GSK) share price is at $38.53, after a 0.62% drop. Over the past month, the stock spiked by 2.75%, but over the past year, it... 
Via Benzinga
Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT... 
Via Benzinga
CureVac's COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed
CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data.... 
Via Benzinga
Exposures COVID-19
2 Deeply Discounted Dividend Stocks to Buy and Hold Right Now
These pharmaceutical companies might make great long-term additions to your portfolio. 
Via The Motley Fool
New New Deal Worries
Nio is up 1.4% today on another round of Meme buying. 
Via Talk Markets
Activist Hedge Fund Elliott Management Backs Away from Forced GlaxoSmithKline's Vaccines, Pharma Business Sale: The Times
The Times of London reports that activist investor Paul Singer's hedge fund Elliott Management will not push the sale of GlaxoSmithKline Plc’s (NYSE... 
Via Benzinga
The Surprising Move Vir Stock Made After Winning Covid Drug Authorization
GlaxoSmithKline and Vir Biotechnology won Food and Drug Administration authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. 
Via Investor's Business Daily
Exposures COVID-19
Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine
Sanofi SA and GlaxoSmithKline plc have launched a Phase 3 trial for its recombinant COVID-19 vaccine candidate, which they hope to get approved by the end of 2021. 
Via Talk Markets
Exposures COVID-19
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug
The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc (NASDAQ: VIR) and ... 
Via Benzinga
Exposures COVID-19 Product Safety
Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) have launched a Phase 3 trial for its recombinant COVID-19 vaccine candidate, which they hope... 
Via Benzinga
Exposures COVID-19
Market Briefing For Thursday, May 27
Dynamics spurring last year's upside, mostly sputtered with sector-rotation since early February. Periodically breadth broadens out slightly and a move in unison occurs, absent sustainability. 
Via Talk Markets
Good Times For Gold
Gold is rising some more, in part as an alternative to crypto. 
Via Talk Markets
FDA May Not Review New COVID-19 Vaccine Emergency Use Requests
The FDA, on Tuesday, said that it might decline to review and process new emergency use authorization (EUA) requests for COVID-19 vaccines for the rest of the pandemic... 
Via Benzinga
Exposures COVID-19 Product Safety
GlaxoSmithKline - Vir Biotech's Antibody COVID-19 Treatment Wins CHMP's Positive Scientific Opinion
The European Medicines Agency’s advisory group, Committee for Human Medicinal Products (CHMP), has concluded that GlaxoSmithKline plc (NYSE: GSK) and Vir... 
Via Benzinga
Exposures COVID-19
Better Mood Day
The US Treasury plans to require IRS reporting on US cryptocurrency trades of $10,000 and up to prevent tax evasion. 
Via Talk Markets
GSK Exits Respiratory Partner Innoviva In $392M Deal
GlaxoSmithKline plc (NYSE: GSK) has agreed to sell 32 million shares in Innoviva Inc (NASDAQ: INVA) back to the royalty management company, raising $392... 
Via Benzinga
Cramer Shares His Thoughts On Marvell, MicroVision, More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Cerence Inc (NASDAQ: CRNC) is just one more software company. He doesn't want to play. Cramer wants great... 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.